AT-56 is primarily utilized in research settings as a selective inhibitor of 5-lipoxygenase (5-LOX), an enzyme critical in the arachidonic acid pathway that leads to the synthesis of leukotrienes. Leukotrienes are key inflammatory mediators involved in allergic responses, asthma, and other inflammatory conditions.

By inhibiting 5-LOX, AT-56 enables researchers to investigate the mechanisms of inflammation, particularly the role of leukotriene production in diseases such as bronchial asthma, rheumatoid arthritis, and inflammatory bowel disease. It is commonly employed in cellular and animal models to assess the anti-inflammatory effects of LOX inhibition and to explore downstream signaling pathways affected by reduced leukotriene levels.

In drug development, AT-56 serves as a valuable tool compound for screening and validating novel 5-LOX inhibitors. Its selectivity helps differentiate the functions of 5-LOX from other lipoxygenases, aiding in the design of targeted therapies that minimize off-target effects. This is essential for understanding lipid-mediated inflammation and developing treatments for chronic inflammatory disorders.

Additionally, AT-56 is used in studies examining the interplay between lipid metabolism and immune responses, including potential applications in cardiovascular diseases and cancer where inflammation plays a role. Overall, AT-56 is an important reagent in biochemical, immunological, and pharmacological research, advancing knowledge of inflammatory pathways and therapeutic interventions.